The prognostic value of cartilage intermediate layer protein 1 (CILP1) in patients with diabetic cardiomyopathy
Abstract Objective To measure the plasma levels of human cartilage intermediate layer protein 1 (CILP1) in patients with diabetic cardiomyopathy (DCM), and to investigate its association with the occurrence of major adverse cardiovascular events (MACE) in DCM. Methods A total of 336 diabetic patient...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2024-11-01
|
| Series: | BMC Cardiovascular Disorders |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12872-024-04331-x |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846165580463210496 |
|---|---|
| author | Li Xiang Xiang Liu Xuehua Jiao Zhenguo Qiao |
| author_facet | Li Xiang Xiang Liu Xuehua Jiao Zhenguo Qiao |
| author_sort | Li Xiang |
| collection | DOAJ |
| description | Abstract Objective To measure the plasma levels of human cartilage intermediate layer protein 1 (CILP1) in patients with diabetic cardiomyopathy (DCM), and to investigate its association with the occurrence of major adverse cardiovascular events (MACE) in DCM. Methods A total of 336 diabetic patients were enrolled and assigned into two groups based on the presence or absence of DCM (DCM group and N-DCM group). The baseline clinical data including glutamic-pyruvic transaminase (ALT), glutamic oxaloacetic acid transferase (AST), albumin, serum creatinine, glycosylated hemoglobin (HbA1c), C-reactive protein (CRP), and N-terminal pro brain natriuretic peptide (NT-proBNP) were recorded. Subsequently, plasma levels of CILP1 at admission were detected by the enzyme linked immunosorbent assay (ELISA) method. Echocardiographic parameters were also acquired for all patients. The association of CILP1 with LVEF, LVDD and CRP was determined. In addition, the occurrence of MACE was examined during the 12-month follow-up in the DCM group. Results The concentration of CILP1 in the DCM group was higher than in the N-DCM group [1329.97 (1157.14, 1494.36) ng/L vs. 789.00 (665.75, 937.06) ng/L, P < 0.05], higher in the MACE group than in the non-MACE group [1777.23 (1532.83, 2341.26)ng/L vs. 885.00 (722.40, 1224.91) ng/L, P < 0.05). Correlation analysis revealed that CILP1 expression was associated with LVEF, CRP and LVDD (r = -0.58, 0.29 and 0.44, respectively, P < 0.05). Analysis of a nomogram demonstrated that CILP1, sex, age, BMI, LVEF and LVDD could predict the occurrence of MACE in DCM patients at 12 months (P < 0.05). The plasma levels of CILP1 were independently associated with a stronger discriminating power for DCM. Furthermore, inclusion of CILP1 as a covariate in the model caused a significant improvement in risk estimation compared with traditional risk factors for DCM [BASIC: AUC: 0.556, 95%CI: 0.501–0.610; BASIC + CILP1: AUC: 0.913, 95%CI: 0.877–0.941, P < 0.05] and MACE [BASIC: AUC: 0.710, 95%CI: 0.616–0.792; BASIC + CILP1: AUC: 0.871, 95%CI: 0.794–0.928, P < 0.05]. Conclusions The serum concentration of CILP1 was increased in DCM patients. Elevated fasting plasma CILP1 levels was a robust diagnostic marker of DCM and was independently associated with an increased risk of MACE. |
| format | Article |
| id | doaj-art-cbc5f51a46c346208328d94812b88b8b |
| institution | Kabale University |
| issn | 1471-2261 |
| language | English |
| publishDate | 2024-11-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Cardiovascular Disorders |
| spelling | doaj-art-cbc5f51a46c346208328d94812b88b8b2024-11-17T12:08:54ZengBMCBMC Cardiovascular Disorders1471-22612024-11-0124111010.1186/s12872-024-04331-xThe prognostic value of cartilage intermediate layer protein 1 (CILP1) in patients with diabetic cardiomyopathyLi Xiang0Xiang Liu1Xuehua Jiao2Zhenguo Qiao3Department of Cardiology, the Second Affiliated Hospital of Soochow UniversityDepartment of Cardiology, the Second Affiliated Hospital of Soochow UniversityDepartment of Endocrinology, Suzhou Ninth People’s Hospital, Suzhou Ninth Hospital Affiliated to Soochow UniversityDepartment of Gastroenterology, Suzhou Ninth People’s Hospital, Suzhou Ninth Hospital Affiliated to Soochow UniversityAbstract Objective To measure the plasma levels of human cartilage intermediate layer protein 1 (CILP1) in patients with diabetic cardiomyopathy (DCM), and to investigate its association with the occurrence of major adverse cardiovascular events (MACE) in DCM. Methods A total of 336 diabetic patients were enrolled and assigned into two groups based on the presence or absence of DCM (DCM group and N-DCM group). The baseline clinical data including glutamic-pyruvic transaminase (ALT), glutamic oxaloacetic acid transferase (AST), albumin, serum creatinine, glycosylated hemoglobin (HbA1c), C-reactive protein (CRP), and N-terminal pro brain natriuretic peptide (NT-proBNP) were recorded. Subsequently, plasma levels of CILP1 at admission were detected by the enzyme linked immunosorbent assay (ELISA) method. Echocardiographic parameters were also acquired for all patients. The association of CILP1 with LVEF, LVDD and CRP was determined. In addition, the occurrence of MACE was examined during the 12-month follow-up in the DCM group. Results The concentration of CILP1 in the DCM group was higher than in the N-DCM group [1329.97 (1157.14, 1494.36) ng/L vs. 789.00 (665.75, 937.06) ng/L, P < 0.05], higher in the MACE group than in the non-MACE group [1777.23 (1532.83, 2341.26)ng/L vs. 885.00 (722.40, 1224.91) ng/L, P < 0.05). Correlation analysis revealed that CILP1 expression was associated with LVEF, CRP and LVDD (r = -0.58, 0.29 and 0.44, respectively, P < 0.05). Analysis of a nomogram demonstrated that CILP1, sex, age, BMI, LVEF and LVDD could predict the occurrence of MACE in DCM patients at 12 months (P < 0.05). The plasma levels of CILP1 were independently associated with a stronger discriminating power for DCM. Furthermore, inclusion of CILP1 as a covariate in the model caused a significant improvement in risk estimation compared with traditional risk factors for DCM [BASIC: AUC: 0.556, 95%CI: 0.501–0.610; BASIC + CILP1: AUC: 0.913, 95%CI: 0.877–0.941, P < 0.05] and MACE [BASIC: AUC: 0.710, 95%CI: 0.616–0.792; BASIC + CILP1: AUC: 0.871, 95%CI: 0.794–0.928, P < 0.05]. Conclusions The serum concentration of CILP1 was increased in DCM patients. Elevated fasting plasma CILP1 levels was a robust diagnostic marker of DCM and was independently associated with an increased risk of MACE.https://doi.org/10.1186/s12872-024-04331-xCartilage intermediate layer protein 1Diabetic cardiomyopathy |
| spellingShingle | Li Xiang Xiang Liu Xuehua Jiao Zhenguo Qiao The prognostic value of cartilage intermediate layer protein 1 (CILP1) in patients with diabetic cardiomyopathy BMC Cardiovascular Disorders Cartilage intermediate layer protein 1 Diabetic cardiomyopathy |
| title | The prognostic value of cartilage intermediate layer protein 1 (CILP1) in patients with diabetic cardiomyopathy |
| title_full | The prognostic value of cartilage intermediate layer protein 1 (CILP1) in patients with diabetic cardiomyopathy |
| title_fullStr | The prognostic value of cartilage intermediate layer protein 1 (CILP1) in patients with diabetic cardiomyopathy |
| title_full_unstemmed | The prognostic value of cartilage intermediate layer protein 1 (CILP1) in patients with diabetic cardiomyopathy |
| title_short | The prognostic value of cartilage intermediate layer protein 1 (CILP1) in patients with diabetic cardiomyopathy |
| title_sort | prognostic value of cartilage intermediate layer protein 1 cilp1 in patients with diabetic cardiomyopathy |
| topic | Cartilage intermediate layer protein 1 Diabetic cardiomyopathy |
| url | https://doi.org/10.1186/s12872-024-04331-x |
| work_keys_str_mv | AT lixiang theprognosticvalueofcartilageintermediatelayerprotein1cilp1inpatientswithdiabeticcardiomyopathy AT xiangliu theprognosticvalueofcartilageintermediatelayerprotein1cilp1inpatientswithdiabeticcardiomyopathy AT xuehuajiao theprognosticvalueofcartilageintermediatelayerprotein1cilp1inpatientswithdiabeticcardiomyopathy AT zhenguoqiao theprognosticvalueofcartilageintermediatelayerprotein1cilp1inpatientswithdiabeticcardiomyopathy AT lixiang prognosticvalueofcartilageintermediatelayerprotein1cilp1inpatientswithdiabeticcardiomyopathy AT xiangliu prognosticvalueofcartilageintermediatelayerprotein1cilp1inpatientswithdiabeticcardiomyopathy AT xuehuajiao prognosticvalueofcartilageintermediatelayerprotein1cilp1inpatientswithdiabeticcardiomyopathy AT zhenguoqiao prognosticvalueofcartilageintermediatelayerprotein1cilp1inpatientswithdiabeticcardiomyopathy |